Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Pharmaceutical Business Review
Return to: PBR Home
Search Refinements

News

View news from other Pharmaceutical sectors:
136-150 of 47315 results
Argos completes patient enrollment in Phase III ADAPT trial of AGS-003
Argos Therapeutics, an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, announced the pivotal phase 3 ADAPT clinical trial of AGS-003 in combination with standard targeted therapy for the treatment of metastatic renal cell carcinoma (mRCC) has reached its enrollment goal of at least 450 randomized patients.
Automation > IT & Software > News
Premama expands with two new Pill-Free supplement solutions for expecting and new moms
Premama, the first nationwide line of natural powdered drink mixes specifically formulated to support the nutritional needs of expecting and new moms, announced the introduction of two new pill-free solutions formulated to address preconception through postpartum concerns beyond prenatal wellness.
Production & Manufacturing > OTC > News
Five Prime Therapeutics enters into research collaboration, license agreement with Inhibrx for new GITR antibodies
Five Prime Therapeutics, a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced a strategic research collaboration and license agreement with Inhibrx for Inhibrx's novel glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody program, which is currently at lead selection stage.
Contract Research & Services > Contract Research > News
Celgene agrees to acquire Receptos for $7.2bn
By PBR Staff Writer
US-based biopharmaceutical firm Celgene is expanding its inflammation and immunology (I&I) portfolio by agreeing to acquire Receptos, for around $7.2bn.
Production & Manufacturing > Manufacturing > News
Nutra Pharma submits orphan drug application to FDA for RPI-78M to treat multiple sclerosis
By PBR Staff Writer
US-based biotechnology firm Nutra Pharma has filed an application with the US Food and Drug Administration (FDA) for orphan drug status of its drug candidate, RPI-78M, to treat multiple sclerosis in children.
Production & Manufacturing > OTC > News
Rexahn gets patent in Japan for new targeted cancer drug delivery platform
Rexahn Pharmaceuticals, a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, announced that it was issued patent number 5749273 from the Japanese Patent Office entitled "Polymeric Systems for the Delivery of Anticancer Drugs" for the company's novel CPMA drug delivery platform.
Drug Research > Drug Delivery > News
Merz Pharma gets Health Canada approval for Radiesse (+) with integral 0.3% lidocaine
Merz Pharma Canada, an affiliate of the global Merz Pharma Group, announced that Radiesse (+) with integral 0.3% Lidocaine (“Radiesse Plus“) has received Health Canada approval and will be available to Canadian physicians in July 2015.
Drug Research > Drug Delivery > News
Medgenics begins enrollment in Phase II trial of TARGT-EPO to treat anemia in ESRD patients
By PBR Staff Writer
Medgenics has started patient enrollment in its US-based Phase II clinical trial of MDGN-201 (TARGTEPO), an investigational gene therapy to treat anemia in end stage renal disease (ESRD) patients undergoing peritoneal dialysis.
Automation > IT & Software > News
FDA grants orphan status for Immunovaccine's DPX-Survivac to treat ovarian cancer
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted orphan drug status for Immunovaccine's clinical-stage cancer immunotherapy, DPX-Survivac, for the treatment of ovarian cancer.
Drug Research > Drug Delivery > News
CANbridge to develop and commercialize Apogenix’s APG101 in glioblastoma for China
By PBR Staff Writer
US-based CANbridge Life Sciences has entered into an exclusive license agreement with Apogenix, to develop, manufacture and commercialize the latter's lead product, APG101.
Contract Research & Services > Contract Services > News
Iroko enters into licensing agreement with Laboratorios Saval for Zorvolex
By PBR Staff Writer
Iroko Pharmaceuticals has entered into a licensing agreement with Laboratorios Saval for the exclusive rights to market and sell Zorvolex (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), in an additional five countries in South America.
Contract Research & Services > Contract Services > News
Bristol-Myers, MUSC to explore new treatments for fibrotic diseases
By PBR Staff Writer
Bristol-Myers Squibb (BMS) and the Medical University of South Carolina (MUSC) have entered into a translational research collaboration to focus on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis.
Contract Research & Services > Contract Research > News
Blaze Bioscience announces open enrollment for Phase I trial of tumor paint BLZ-100
Blaze Bioscience, the Tumor Paint Company, a biotechnology company focused on guided cancer therapy, announced expansion of its Phase 1 program into multiple additional tumor types.
Drug Research > Drug Delivery > News
Scioderm to submit rolling NDA to FDA for Zorblisa
Scioderm, a clinical-stage biopharmaceutical company focused on developing innovative therapies for treating diseases with high unmet need, including rare diseases, announced that it has agreed with the US Food and Drug Administration (FDA) to submit a rolling New Drug Application (NDA) submission for Zorblisa (SD-101), a proprietary and novel topical therapy for the treatment of blisters and lesions in patients with Epidermolysis Bullosa (EB), a rare genetic connective tissue disorder.
Regulatory Affairs > News
USPTO issues notice of allowance for patent using TB4 for improving neurological outcomes after injury and neurodegenerative disease
RegeneRx Biopharmaceuticals, a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced that the US Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent covering the administration of Thymosin beta 4 (TB4) to improve neurological outcome after neurological injury and neurodegenerative disease, including stroke and traumatic brain injury (TBI).
Production & Manufacturing > Process & Production > News
136-150 of 47315 results